RxDoctor Payments Data

Rebecca Wolfe, MD

Psychiatry · Cedar Rapids, IANPI 1215146055

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.5% of the total across 66 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Supernus Pharmaceuticals, Inc. accounts for 73.1% of it on its own, with 6 other manufacturers making up the rest.

$1,275in general payments, 2019–2025

Across 66 payments — averaging $19.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Supernus Pharmaceuticals, Inc.$932
  • Adlon Therapeutics L.p.$116
  • E.r. Squibb & Sons, L.L.C.$93
  • Corium, LLC$84
  • Ironshore Pharmaceuticals Inc.$22
  • Harmony Biosciences LLC$14
  • plus $14 from 1 others

What the payments were for

  • Food & beverage$1,26899%
  • Education$71%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,275 in reported general payments places this provider in the 80th percentile of 245 psychiatry providers in Iowa.

See all psychiatry providers in Iowa

Medicare billing

Part B allowed, 2024
$6,777
Medicare patients
27
Services billed
71

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate11$34,093
CaplytaLumateperone Tosylate12$19,618
Dextroamphetamine Sulfate11$1,487
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine47$1,449
Vilazodone Hcl16$1,376
Aripiprazole16$1,257
Clozapine29$1,195
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine24$1,090
Hydroxyzine Hcl17$870
Bupropion XlBupropion Hcl53$830
Divalproex Sodium ErDivalproex Sodium31$620
Fluoxetine Hcl35$542
Sertraline Hcl65$534
Olanzapine31$462
Risperidone29$408

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$14$34,09311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 245 psychiatry providers in Iowa.

Other psychiatry in Cedar Rapids

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →